Affymetrix Inc., of Santa Clara, Calif., said it received U.S. Patent No. 6,225,625 titled ¿Signal Detection Methods and Apparatus.¿ It covers an apparatus for detecting nucleic acids on a support containing oligonucleotides, polynucleotides or nucleic acids.
Agennix Inc., of Houston, said it received U.S. Patent No. 6,228,614. It covers a method for expressing human lactoferrin in eukaryotic cells.
Biomira Inc., of Edmonton, Alberta, said it received U.S. Patent No. 6,222,020 titled ¿Antigen Derived From the Core Protein of the Human Mammary Epithelial Mucin.¿ It covers the peptide used in Biomira¿s BLP25 liposomal cancer vaccine.
Biospherics Inc., of Beltsville, Md., received a U.S. patent covering the use of tagatose as a drug to improve fertility.
Ciphergen Biosystems Inc., of Fremont, Calif., said it received U.S. Patent No. 6,225,047. It covers a novel protein expression profiling method for protein biomarker discovery.
Corixa Corp., of Seattle, said it received U.S. Patent Nos. 6,183,976; 6,207,169; and 6,214,971. They cover compositions of matter and methods for diagnostics and treatment of B. microti infection and Ehrlichia infection, particularly human granulocytic ehrlichiosis.
Dendreon Corp., of Seattle, said it received U.S. Patent No. 6,210,662. It covers the therapeutic composition of Provenge, Dendreon¿s lead product for treatment of advanced prostate cancer.
Ecopia BioSciences Inc., of Saint-Laurent, Quebec, said it filed a group of 10 patent applications for gene-based products and processes.